Enlivex Therapeutics Ltd. Quarterly Depreciation in USD from Q2 2019 to Q2 2022

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Enlivex Therapeutics Ltd. annual/quarterly Depreciation history and growth rate from Q2 2019 to Q2 2022.
  • Enlivex Therapeutics Ltd. Depreciation for the quarter ending June 30, 2022 was $176K, a 44.3% increase year-over-year.
  • Enlivex Therapeutics Ltd. annual Depreciation for 2023 was $835K, a 7.47% increase from 2022.
  • Enlivex Therapeutics Ltd. annual Depreciation for 2022 was $777K, a 42.3% increase from 2021.
  • Enlivex Therapeutics Ltd. annual Depreciation for 2021 was $546K, a 90.9% increase from 2020.
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2022 $176K +$54K +44.3% Apr 1, 2022 Jun 30, 2022 6-K 2022-08-22
Q2 2021 $122K +$62K +103% Apr 1, 2021 Jun 30, 2021 6-K 2022-08-22
Q2 2020 $60K -$32K -34.8% Apr 1, 2020 Jun 30, 2020 6-K/A 2020-10-13
Q2 2019 $92K Apr 1, 2019 Jun 30, 2019 6-K/A 2020-10-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.